STOCK TITAN

BeyondSpring Inc. - $BYSI STOCK NEWS

Welcome to our dedicated page for BeyondSpring news (Ticker: $BYSI), a resource for investors and traders seeking the latest updates and insights on BeyondSpring stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BeyondSpring's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BeyondSpring's position in the market.

Rhea-AI Summary
BeyondSpring Inc. has regained compliance with the minimum bid price requirement set forth by Nasdaq. The closing bid price of the company's ordinary shares has been at $1.00 per share or greater for 10 consecutive business days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
none
-
Rhea-AI Summary
SEED Therapeutics Inc. announced the discovery of a new chemical entity (NCE) molecular glue for the treatment of cancers. The molecule has achieved IND Candidate status and will be advanced for clinical testing in 2024. The company's progress reflects the potential of targeted protein degradation (TPD) science.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
none
-
Rhea-AI Summary
SEED Therapeutics appoints international lawyer Ko-Yung Tung to its Board of Directors. Tung brings 50 years of experience in global health, law, governance, and international business. SEED focuses on engineering 'molecular glues' and targeted protein degradation (TPD) to attack undruggable targets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
management
Rhea-AI Summary
BeyondSpring Inc. received a notification from Nasdaq stating that it is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The company has 180 calendar days to regain compliance. If it fails to do so, it may be eligible for an additional 180-day compliance period. The notification does not affect the company's business operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
none
-
Rhea-AI Summary
BeyondSpring Inc. announces presentation at SITC's Annual Meeting on November 3-5 in San Diego, CA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.98%
Tags
conferences
-
Rhea-AI Summary
BeyondSpring to present at R.W. Baird's Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.47%
Tags
management
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.78%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.59%
Tags
none
BeyondSpring Inc.

Nasdaq:BYSI

BYSI Rankings

BYSI Stock Data

104.40M
23.87M
26.47%
14.06%
6.08%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
New York

About BYSI

beyondspring pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. we are currently advancing the development of our lead asset plinabulin, a novel cancer therapeutic, in a global phase 3 trial in non-small-cell lung cancer (nsclc) and initiating a pivotal global phase 3 trial in prevention of docetaxel-induced neutropenia. as a tubulin depolymerizing agent, plinabulin works via multiple mechanisms of action to target and alter the tumor microenvironment: 1. immune enhancing effects via dendritic cell maturation 2. tumor cell apoptosis via activation of ras-jnk pathway 3. vascular disruptive effects given plinabulin’s potential as a tumor micro-environment targeting agent, we intend to initiate clinical trials in additional cancer indications: • immuno-oncology, with immune checkpoint inhibitors in nsclc • cns malignancies including glioblastoma (gbm) • kras positive mutant cancers